24 completed, 10 terminated, 6 unknown, 3 recruiting. 48 Phase 1, 24 Phase 2.
Follow Graft Versus Host Disease: new trials by email Literature Review of Graft Versus Host Disease trials Research Report on Graft Versus Host Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluating the Effects of Propionate and Butyrate Supplementation on the Intestinal Health of Healthy Volunteers Biospecimen Collection, Microencapsulated Sodium Butyrate, Microencapsulated Sodium Propionate - Graft Versus Host Disease, Hematopoietic and Lymphatic System Neoplasm | Phase 1 | Not yet recruiting | City of Hope Medical Center | 12 | 2026-09-30 | 2026-05-28 |
| Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant Biospecimen Collection, Busulfan, Computed Tomography - Acute Myeloid Leukemia, Graft Versus Host Disease | Phase 1 | Recruiting | City of Hope Medical Center | 15 | 2026-06-12 | 2026-07-01 |
| Sequential Administration of WJ-MSCs for the Treatment of GvHD Refractory to Second Line Treatment Wharton's jelly mesenchymal stem cells (WJ-MSCs) - Graft Versus Host Disease | Phase 1 / Phase 2 | Unknown | Fundación Oftalmológica de Santander Clínica Carlos Ardila Lulle | 10 | 2024-06-01 | 2024-03-12 |
| Ruxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation Ruxolitinib, Abatacept - Graft Vs Host Disease, Graft-versus-host-disease | Phase 1 | Recruiting | Washington University School of Medicine | 41 | 2024-05-07 | 2026-04-22 |
| A Prospective, Open Label, Dose-escalation, SAD/MAD, Multicenter, 24weeks, Phase I/IIa Clinical Trial to Evaluate the Safety, Tolerability and Pharmacodynamics of Investigational Product (VM-001) in Patients With Graft-versus-host Disease(GvHD) VM-001 1X10^6 cells/kg, VM-001 3X10^6 cells/kg, VM-001 5X10^6 cells/kg - Graft Versus Host Disease | Phase 1 / Phase 2 | Unknown | ViGenCell Inc. | 12 | 2022-11-20 | 2022-03-11 |
| PTCY Plus uhCG/EGF for Graft Versus Host Disease Prophylaxis uhCG/EGF - Graft Versus Host Disease | Phase 1 | Recruiting | Henry Ford Health System | 18 | 2021-12-23 | 2026-02-24 |
| Optimizing PTCy Dose and Timing Busulfan, Fludarabine, Cyclophosphamide - Graft Versus Host Disease, Hematologic Neoplasms | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 105 | 2019-07-09 | 2025-12-26 |
| T Lymphocytes (LT) Expressing iCASP9 and ΔCD19 in Allogeneic Haematopoietic Transplantation. T lymphocytes iCASP9 ΔCD19, Dimerizer drug AP1903 - Graft Versus Host Disease, Hematological Malignancies | Phase 1 / Phase 2 | Terminated | Centre Hospitalier Universitaire de Besancon | 2 | 2019-04-10 | 2025-07-09 |
| Detection of Graft Versus Host Disease With [18F]F-AraG [18F]F-Ara-G - Graft Versus Host Disease | Phase 1 | Completed | CellSight Technologies, Inc. | 9 | 2018-05-15 | 2025-12-08 |
| Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Fludarabine Phosphate - Acute Myeloid Leukemia in Remission, Adult Acute Lymphoblastic Leukemia in Complete Remission | Phase 1 / Phase 2 | Active not recruiting | Roswell Park Cancer Institute | 35 | 2017-08-09 | 2026-04-14 |
| Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease Diphenhydramine, Acetaminophen, Methylprednisolone - Sickle Cell Disease, Graft Versus Host Disease | Phase 1 | Completed | Monica Bhatia | 24 | 2016-07-01 | 2024-06-13 |
| Donor Regulatory T Cells in Treating Patients With Visceral Acute Graft-versus-Host Disease After Stem Cell Transplant donor regulatory T lymphocytes, laboratory biomarker analysis - Graft Versus Host Disease | Phase 1 | Withdrawn | Everett Meyer | 2015-08-06 | 2023-11-22 | |
| BMT Autologous MSCs for GvHD Autologous mesenchymal stromal cells (MSCs) - Graft Versus Host Disease, Acute Graft Versus Host Disease | Phase 1 | Completed | Emory University | 11 | 2015-01-01 | 2023-01-12 |
| Allogenic Bone Marrow Mesenchymal Stem Cells Infusion in Patients With Steroid-refractory GVHD Mesenchymal Stem Cells - Graft Versus Host Disease | Phase 1 / Phase 2 | Completed | National Institute of Blood and Marrow Transplant (NIBMT), Pakistan | 10 | 2015-01-01 | 2017-01-25 |
| Ex-vivo Expanded Donor Regulatory T Cells for Prevention of Acute Graft-Versus-Host Disease Cultured Treg cells - Graft Versus Host Disease | Phase 1 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 38 | 2014-10-29 | 2022-11-03 |
| Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Chronic Graft Versus Host Disease Ibrutinib - Graft Versus Host Disease | Phase 1 / Phase 2 | Completed | Pharmacyclics LLC. | 45 | 2014-07-14 | 2019-07-11 |
| Phase I Trial of LDE225 for Steroid-refractory Chronic GVHD After Allogeneic HSCT LDE225 - Graft Versus Host Disease | Phase 1 | Terminated | Massachusetts General Hospital | 17 | 2014-04-01 | 2018-03-19 |
| Phase 1 Infused Donor T Regulatory Cells in Steroid Dependent/Refractory Chronic GVHD Regulatory T Cells - Graft Versus Host Disease, Allogeneic Hematopoietic Cell Transplant Recipient | Phase 1 | Completed | Laura Johnston | 14 | 2013-07-01 | 2021-09-27 |
| Cannabidiol for Graft Versus Host Disease (GVHD) Prophylaxis in Allogeneic Stem Cell Transplantation Oral Cannabidiol - Graft Versus Host Disease | Phase 1 / Phase 2 | Unknown | Rabin Medical Center | 30 | 2012-09-01 | 2015-06-19 |
| Bortezomib in Patients With Chronic Graft Versus Host Disease Bortezomib - Graft Versus Host Disease | Phase 1 | Completed | Mehrdad Abedi, MD | 16 | 2012-07-01 | 2020-05-28 |
Showing 20 of 48. Sign in to see all of them.
Graft vs Host Disease (48) · Myelodysplastic Syndromes (16) · Leukemia (15) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (12) · Leukemia, Myeloid, Acute (11) · Lymphoma (11) · Multiple Myeloma (11) · Neoplasms, Plasma Cell (11) · Leukemia, Lymphocytic, Chronic, B-Cell (10) · Lymphoma, Follicular (10) · Burkitt Lymphoma (9) · Lymphoma, Large B-Cell, Diffuse (9) · Lymphoma, Large-Cell, Immunoblastic (9) · Lymphoma, Mantle-Cell (9) · Lymphoma, Non-Hodgkin (9)
Immune System Diseases (47) · Hematologic Diseases (22) · Hemic and Lymphatic Diseases (22) · Neoplasms (21) · Neoplasms by Histologic Type (18) · Bone Marrow Diseases (17) · Chronic Disease (15) · Disease Attributes (15) · Immunoproliferative Disorders (15) · Leukemia, Myeloid (15) · Lymphatic Diseases (15) · Lymphoproliferative Disorders (15) · Pathologic Processes (15) · Pathological Conditions, Signs and Symptoms (15) · Leukemia, Lymphoid (13)
Cyclophosphamide (11) · Sirolimus (9) · Tacrolimus (9) · Methotrexate (8) · Mycophenolic Acid (8) · Peripheral Blood Stem Cell Transplantation (7) · Cyclosporine (6) · Melphalan (6) · Busulfan (5) · fludarabine (5) · fludarabine phosphate (5) · Filgrastim (4) · Methylprednisolone (4) · Alemtuzumab (3) · Whole-Body Irradiation (3)
Fred Hutchinson Cancer Center (6) · City of Hope Medical Center (2) · Dana-Farber Cancer Institute (2) · Masonic Cancer Center, University of Minnesota (2) · Massachusetts General Hospital (2) · Northwestern University (2) · Rabin Medical Center (2) · Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud (1) · CellSight Technologies, Inc. (1) · Centre Hospitalier Universitaire de Besancon (1) · Emory University (1) · Everett Meyer (1) · Fundación Oftalmológica de Santander Clínica Carlos Ardila Lulle (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Hackensack Meridian Health (1)
United States (37) · Israel (3) · France (1) · Germany (1) · Pakistan (1) · Spain (1)
H. Joachim Deeg, MD (2) · Moshe Yeshurun, MD (2) · Richard K. Burt, MD (2) · Amandeep Salhotra (1) · Andrew Artz, M.D. (1) · Ann E. Woolfrey, MD (1) · Bimalangshu R. Dey, MD, PhD (1) · Carlos Solano Vercet, MD (1) · Carol A. Huff, MD (1) · Chang-Ki Min, MD, Ph.D. (1) · Christopher G Kanakry, M.D. (1) · Christos E. Emmanouilides, MD (1) · Claudio G. Brunstein, MD, PhD (1)
PMID 22129252, PMID 24140121, PMID 24530972, PMID 26033282, PMID 28924018, PMID 29296838, PMID 31260802, PMID 34102349, PMID 36189324, PMID 39908565, PMID 42322116
P30CA033572 (2), P01CA015396 (1), P01CA049605 (1), P30CA006516 (1), P30CA006973 (1), P30CA015704 (1)